Atara Biotherapeutics, Inc. Common Stock and Pre-Funded Warrants Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $150 million SEC-registered common stock and pre-funded warrants offering by Atara Biotherapeutics, Inc. Atara’s common stock is listed on the Nasdaq Global Market under the symbol “ATRA.”

Based in South San Francisco, California, Atara is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.

The Davis Polk corporate team included partners Bruce K. Dallas and Sarah K. Solum and associates Josephine Chen and Caitlin Moyles Cunnane. The tax team included partner Rachel D. Kleinberg and associate Shay Moyal. Associate Jay Frankel provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.